실험적 피부포도알균 안내염에서 가티플록사신의 유리체강내 주사의 효과

다국어 초록 (Multilingual Abstract)

Purpose: To compare the efficacy of intravitreal gatifloxacin with intravitreal vancomycin in the treatment of Staphylococcus epidermidis endophthalmitis in a rabbit model. Methods: Albino rabbits (n=30), infected with an intravitreal inoculum of S. epidermidis (105 colony forming unit/0.1 mL), were divided into 6 groups (n=5). Groups I and IV received 200 μg/0.1 mL of intravitreal gatifloxacin, and groups II and V were injected 1000 μg/0.1 mL of vancomycin intravitreally. Intravitreal balanced salt solutions (untreated control) were given to Groups III and VI. Intravitreal antibiotic therapy commenced 24 hours after bacterial inoculation. The bactericidal efficacy was determined by electroretinography (ERG), clinical grading, bacterial culture of vitreous aspirates and histopathologic grading. ERGs and clinical gradings were performed only for groups I, II, and III and bacterial cultures were done only for groups IV, V, and VI. Results: Eyes in the gatifloxacin groups showed similar appearance to those in the vancomycin treated groups clinically, histologically, and functionally as proved with ERG. All aspirates from the gatifloxacin and vancomycin groups were culture‐negative at 5 days after bacterial inoculation, whereas all eyes in the untreated control group were culture‐positive. Conclusions: This study demonstrated that intravitreal injection of 200 μg /0.1mL gatifloxacin appeared to be equally effective compared to intravitreal 1000 μg /0.1 mL vancomycin in the treatment of S. epidermidis endophthalmitis. If proven safe and efficacious after further study in humans, intravitreal injection of gatifloxacin could be considered an effective alternative to vancomycin for the treatment of S. epidermidis endophthalmitis.

참고문헌 (Reference)

1 최경식, "실험적으로 유발한 Bacillus 안내염에서 유리체강내 Ciprofloxacin의 치료효과" 대한안과학회 43 (43): 890-897, 2002

2 Maxwell DP Jr, "natural history study of experimental Staphylococcus epidermidis endophthalmitis" 12 : 907-912, 1993

3 Saenz Gonzalez MC, "[Enterococcus sp. resistance, a growing problem. Epidemiologic study (1987-1993)]" 103 : 485-489, 1994

4 Hariprasad SM, "Vitreous penetration of orally administered gatifloxacin in humans" 100 : 153-159, 2002

5 Hariprasad SM, "Vitreous and aqueous penetration of orally administered gatifloxacin in humans" 121 : 345-350, 2003

6 Ermis SS, "Treatment of Staphylococcus epidermidis endophthalmitis with intravitreal moxifloxacin in a rabbit model" 205 : 223-229, 2005

7 Ozkiris A, "The efficacy of intravitreal piperacillin/tazobactam in rabbits with experimental Staphylococcus epidermidis endophthalmitis: a comparison with vancomycin" 37 : 168-174, 2005

8 Domagala JM, "Structure‐activity and structure‐side‐effect relationships for the quinolone antibacterials" 33 : 685-706, 1994

9 O'Day DM, "Staphylococcus epidermidis endophthalmitis. Visual outcome following noninvasive therapy" 89 : 354-360, 1982

10 Meredith TA, "Spontaneous sterilization in experimental Staphylococcus epidermidis endophthalmitis" 31 : 181-186, 1990

11 Chung KH, "Spontaneous sterilization in experimental Staphylococcus and Pseudomonas endophthalmitis" 36 : 1895-1902, 1995

12 "Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group" 113 : 1479-1496, 1995

13 Rowen S, "Preoperative and postoperative medications used for cataract surgery" 10 : 29-35, 1999

14 Solomon R, "Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor" 112 : 466-469, 2005

15 Donnenfeld ED, "Penetration of topically applied ciprofloxacin, norfloxacin, and ofloxacin into the aqueous humor" 101 : 902-905, 1994

16 Mather R, "Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics" 133 : 463-466, 2002

17 Engelbert M, "Intravitreal vancomycin and amikacin versus intravenous imipenem in the treatment of experimental Staphylococcus aureus endophthalmitis" 242 : 313-320, 2004

18 Kazi AA, "Intravitreal toxicity of levofloxacin and gatifloxacin" 37 : 224-229, 2006

19 Gao H, "Intravitreal moxifloxacin: retinal safety study with electroretinography and histopathology in animal models" 47 : 1606-1611, 2006

20 Bower KS, "Fluoroquinolones in the treatment of bacterial keratitis" 121 : 712-715, 1996

21 Hwang DG, "Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones" 49 : 79-83, 2004

22 Aydin E, "Esfahani MR. Intravitreal toxicity of moxifloxacin" 26 : 187-190, 2006

23 Esmaeli B, "Endogenous endophthalmitis secondary to vancomycin-resistant enterococci infection" 23 : 118-119, 2003

24 Goldstein MH, "Emerging fluoroquinolone resistance in bacterial keratitis: a 5‐year review" 106 : 1313-1318, 1999

25 Schwalbe RS, "Emergence of vancomycin resistance in coagulase‐negative staphylococci" 316 : 927-931, 1987

26 Loewenstein A, "Drug‐induced retinal toxicity in albino rabbits: the effects of imipenem and aztreonam" 34 : 3466-3476, 1993

27 Meredith TA, "Comparative treatment of experimental Staphylococcus epidermidis endophthalmitis" 108 : 857-860, 1990

28 Recchia FM, "Changing trends in the microbiologic aspects of postcataract endophthalmitis" 123 : 341-346, 2005

29 Roth DB, "Antibiotic selection in the treatment of endophthalmitis: the significance of drug combinations and synergy" 41 : 395-401, 1997

30 Mino De Kaspar H, "Antibiotic resistance pattern and visual outcome in experimentally-induced Staphylococcus epidermidis endophthalmitis in a rabbit model" 108 : 470-478, 2001

31 Hui M, "An in vitro study on the compatibility and precipitation of ciprofloxacin and vancomycin in human vitreous" 88 : 218-222, 2004

32 Kwok AK, "An in vitro study of ceftazidime and vancomycin concentrations in various fluid media: implications for use in treating endophthalmitis" 43 : 1182-1188, 2002

33 Ednie LM, "Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms" 42 : 2459-2462, 1998